

Table S6. Removal of the N276 glycan site affects predominantly VRC01-class antibodies.

The glycan site at N276 was removed by alanine mutagenesis on a cross-clade 6-virus panel and tested for neutralization by VRC01 class antibodies as well as CD4 IgG₂, other CD4bs bnAbs (b12), and CD4bs non-broadly neutralizing antibodies (b6, F105). Presented values are neutralization IC₅₀ in µg/ml and colored according to the listed legend.

WT							Neutralization IC ₅₀ (µg/mL)
	JR-CSF	92TH021	IAVI C22	94UG103	92RW020	JR-FL	50
VRC01	0.225	0.370	0.651	0.164	0.205	0.021	10
MinVRC01	0.080	0.539	0.899	0.483	0.151	0.367	1
MinVRC01 LΔFW3	> 50	> 50	> 50	> 50	> 50	> 50	0.10
MinVRC01 GL-L	> 50	> 50	> 50	> 50	> 50	> 50	0.01
b6	> 50	> 50	> 50	> 50	> 50	> 50	0.001
F105	> 50	> 50	> 50	> 50	> 50	> 50	
CD4 IgG2	1.11	0.325	5.16	0.044	0.434	0.045	
b12	0.590	1.14	8.55	2.02	> 50	0.019	

N276A							
	JR-CSF	92TH021	IAVI C22	94UG103	92RW020	JR-FL	
VRC01	0.063	0.149	0.069	0.026	0.040	0.026	
MinVRC01	0.017	0.048	0.051	0.117	0.033	0.004	
MinVRC01 LΔFW3	0.053	0.038	0.097	0.149	0.055	0.006	
MinVRC01 GL-L	0.057	0.292	0.163	0.215	0.073	0.009	
b6	> 50	> 50	> 50	> 50	> 50	> 50	
F105	> 50	> 50	> 50	> 50	> 50	> 50	
CD4 IgG2	5.20	0.675	19.3	0.166	0.815	0.050	
b12	0.738	3.75	11.3	8.00	> 50	0.016	